Dishman Carbogen [DCAL] vs Supriya Lifescience [SUPRIYA] Detailed Stock Comparison

Dishman Carbogen Amcis Ltd.

NSE
Loading...

Supriya Lifescience Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Dishman Carbogen Amcis Ltd. wins in 8 metrics, Supriya Lifescience Ltd. wins in 11 metrics, with 0 ties. Supriya Lifescience Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Dishman Carbogen Amcis Ltd. Supriya Lifescience Ltd. Better
P/E Ratio (TTM) 22.30 27.94 Dishman Carbogen Amcis Ltd.
Price-to-Book Ratio 0.42 4.78 Dishman Carbogen Amcis Ltd.
Debt-to-Equity Ratio 40.20 0.48 Supriya Lifescience Ltd.
PEG Ratio -0.16 4.65 Supriya Lifescience Ltd.
EV/EBITDA 9.62 19.44 Dishman Carbogen Amcis Ltd.
Profit Margin (TTM) 4.25% 25.19% Supriya Lifescience Ltd.
Operating Margin (TTM) 3.99% 31.61% Supriya Lifescience Ltd.
EBITDA Margin (TTM) 3.99% 31.61% Supriya Lifescience Ltd.
Return on Equity 0.06% 18.86% Supriya Lifescience Ltd.
Return on Assets (TTM) 0.03% 16.90% Supriya Lifescience Ltd.
Free Cash Flow (TTM) $1.58B $22.99M Dishman Carbogen Amcis Ltd.
Dividend Yield N/A 0.27% N/A
1-Year Return -33.95% 41.71% Supriya Lifescience Ltd.
Price-to-Sales Ratio (TTM) 0.95 7.03 Dishman Carbogen Amcis Ltd.
Enterprise Value $46.55B $50.78B Supriya Lifescience Ltd.
EV/Revenue Ratio 1.66 6.90 Dishman Carbogen Amcis Ltd.
Gross Profit Margin (TTM) 80.34% 70.35% Dishman Carbogen Amcis Ltd.
Revenue per Share (TTM) $179 $91 Dishman Carbogen Amcis Ltd.
Earnings per Share (Diluted) $7.58 $23.01 Supriya Lifescience Ltd.
Beta (Stock Volatility) 0.40 0.28 Supriya Lifescience Ltd.

Dishman Carbogen Amcis Ltd. vs Supriya Lifescience Ltd. Stock Performance Analysis

Loading Price Chart...

DCAL
SUPRIYA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dishman Carbogen Amcis Ltd.-2.38%-2.24%-7.21%9.02%-19.76%-29.73%
Supriya Lifescience Ltd.-2.25%3.93%38.73%66.47%32.20%28.93%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dishman Carbogen Amcis Ltd.-33.95%46.77%-6.77%33.46%290.77%118.12%
Supriya Lifescience Ltd.41.71%283.42%102.02%102.02%102.02%102.02%

Performance & Financial Health Analysis: Dishman Carbogen Amcis Ltd. vs Supriya Lifescience Ltd.

MetricDCALSUPRIYA
Market Information
Market Cap i₹26.50B₹51.74B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i337,264200,097
90 Day Avg. Volume i517,904176,231
Last Close₹180.24₹955.20
52 Week Range₹128.50 - ₹321.95₹545.50 - ₹1,085.00
% from 52W High-44.02%-11.96%
All-Time High₹396.40 (Jan 22, 2018)₹1,085.00 (Jun 01, 2026)
% from All-Time High-54.53%-11.96%
Growth Metrics
Quarterly Revenue Growth0.06%0.11%
Quarterly Earnings Growth-0.09%0.06%
Financial Health
Profit Margin (TTM) i0.04%0.25%
Operating Margin (TTM) i0.04%0.32%
Return on Equity (TTM) i0.00%0.19%
Debt to Equity (MRQ) i40.200.48
Cash & Liquidity
Book Value per Share (MRQ)₹405.67₹134.51
Cash per Share (MRQ)₹40.41₹12.82
Operating Cash Flow (TTM) i₹-199,700,000₹1.87B
Levered Free Cash Flow (TTM) i₹32.40M₹1.88B
Dividends
Last 12-Month Dividend Yield iN/A0.27%
Last 12-Month Dividend i₹0.00₹1.80

Valuation & Enterprise Metrics Analysis: Dishman Carbogen Amcis Ltd. vs Supriya Lifescience Ltd.

MetricDCAL (Apr 26, 2026)SUPRIYA (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i22.3027.94
Forward P/E i13.5220.97
PEG Ratio i-0.164.65
Price to Sales (TTM) i0.957.03
Price to Book (MRQ) i0.424.78
Market Capitalization
Market Capitalization i₹26.50B₹51.74B
Enterprise Value i₹46.55B₹50.78B
Enterprise Value Metrics
Enterprise to Revenue i1.666.90
Enterprise to EBITDA i9.6219.44
Risk & Other Metrics
Beta i0.400.28
Book Value per Share (MRQ) i₹405.67₹134.51

Financial Statements Comparison: Dishman Carbogen Amcis Ltd. vs Supriya Lifescience Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricDCAL (2025)SUPRIYA (2025)
Revenue/Sales i26.42B6.80B
Cost of Goods Sold i5.26B2.86B
COGS % of Revenue i19.9%42.1%
Gross Profit i21.16B3.93B
Gross Margin i80.1%57.9%
Research & Development iN/AN/A
Operating Income (EBIT) i1.46B2.36B
Operating Margin i5.5%34.7%
EBITDA i4.83B2.66B
EBITDA Margin i18.3%39.2%
Pre-Tax Income i193.10M2.48B
Pre-Tax Income % of Revenue i0.7%36.6%
Income Tax i160.70M605.23M
Income Tax % of Revenue i0.6%8.9%
Net Income (Profit) i32.40M1.88B
Profit Margin i0.1%27.7%

Balance Sheet & Liquidity Metrics

MetricDCAL (2025)SUPRIYA (2025)
Cash & Equivalents i2.86B759.97M
Total Current Assets i22.00B4.37B
Total Current Assets % of Revenue i83.3%64.3%
Total Current Liabilities i19.25B821.62M
Total Current Liabilities % of Revenue i72.9%12.1%
Long-Term Debt i13.90B50.57M
Long-Term Debt % of Revenue i52.6%0.7%
Total Shareholders Equity i58.32B9.97B
Retained Earnings i2.13B7.82B
Retained Earnings % of Revenue i8.1%115.1%
Property, Plant & Equipment i10.27B645.91M

Cash Flow Statement Comparison

MetricDCAL (2025)SUPRIYA (2025)
Operating Cash Flow i-199.70M1.87B
Operating Cash Flow % of Revenue i-0.8%27.6%
Capital Expenditures i-2.15B-1.62B
Free Cash Flow i1.58B22.99M
FCF Margin i6.0%0.3%
Debt Repayment i-1.10BN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricDCALSUPRIYA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i156.78M80.48M
Float Shares i54.95M25.52M
% Held by Insiders i69.30%70.84%
% Held by Institutions i2.41%4.42%
% Held by Public i28.29%24.74%

Dividend Analysis & Yield Comparison: Dishman Carbogen Amcis Ltd. vs Supriya Lifescience Ltd.

MetricDCALSUPRIYA
Last 12-Month Dividend i₹0.00₹1.80
Last 12-Month Dividend Yield iN/A0.27%
3-Year Avg Annual Dividend i₹0.00₹0.80
3-Year Avg Dividend Yield iN/A0.17%
3-Year Total Dividends i₹0.00₹2.40
Ex-Dividend DateN/ASep 04, 2025